Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis

Advances in Therapy

Volumn 28, Issue 9, 2011, Pages 761-775

  Halpern, Rachel ^a   Agarwal, Sonalee ^b   Borton, Leigh ^a   Oneacre, Kathy ^a   Lopez Bresnahan, Maria V ^c  

^a OPTUM   (United States)

^b BIOGEN   (United States)

^c Medical and Scientific Affairs   (United States)

Author keywords

Drug therapy; Medication adherence; Medication persistence; Multiple sclerosis; Retrospective studies

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG TREATMENT FAILURE; FEMALE; HEALTH INSURANCE; HUMAN; IMMUNOMODULATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UNITED STATES;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INSURANCE CLAIM REVIEW; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; PEPTIDES; PROPORTIONAL HAZARDS MODELS; TREATMENT FAILURE;

EID: 82455212856     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0054-9     Document Type: Article

References (49)

1. National Multiple Sclerosis Society. Just the facts. 2010. Available at: Http://www.nationalmssociety. org/about-multiple-sclerosis/what-we-know-about- ms/what-is-ms/index.aspx. Accessed March 15, 2011
2. Bainbridge JL, Rieckmann P. Multiple sclerosis. In: DiPiro JT, Talbert R, Yee G, Matzke G, eds. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill Medical; 2008: 913-926
3. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010;74(suppl. 3): S3-S7
4. IFNB Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43: 655-661
5. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39: 285-294 (Pubitemid 26100751)
6. PRISMS. Randomised, double-blind, placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352: 1498-1504
7. Biogen Idec, I. Avonex (interferon beta-1a) prescribing information. 2008. Available at: Http:// www.avonex.com/pdfs/pi-luer-lock.pdf. Accessed March 15, 2011
8. Biogen Idec, IaEPI. Tysabri (natalizumab) prescribing information. 2010. Available at: Http:// www.tysabri.com/en-US/tysb/site/pdfs/TYSABRI-pi.pdf. Accessed March 15, 2011
9. EMD Serono, I. Rebif (interferon beta-1a) prescribing information. 2009. Available at: Http:// www.emdserono.com/cmg.emdserono-us/en/images/rebif-tcm115- 19765.pdf. Accessed March 15, 2011
10. Teva Neuroscience, I. Copaxone (glatiramer acette) prescribing information. 2011. Available at: Http://www.sharedsolutions.com/pdfs/ PrescribingInformation.aspx. Accessed March 15, 2011
11. Bayer Healthcare Pharmaceuticals, I. Betaseron (interferon beta-1b) prescribing information. 2010. Available at: Http://berlex.bayerhealthcare. com/html/products/pi/Betaseron-PI.pdf. Accessed March 15, 2011
12. United States Food and Drug Administration. Novantrone (mitoxantrone) drug label. 2010. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/ label/2010/019297s033s034lbl. pdf. Accessed March 15, 2011
13. Novartis Pharmaceuticals Corp. Extavia (interferon beta-1b) prescribing information. 2009. Available at: Http://www.pharma.us.novartis.com/product/ pi/pdf/extavia.pdf. Accessed March 15, 2011
14. Novartis Pharmaceuticals Corp. Gilenya (fingolimod) prescribing information. 2010. Available at: Http://www.pharma.us.novartis.com/ product/pi/pdf/gilenya.pdf. Accessed March 15, 2011
15. World Health Organization. Adherence to long-term therapies: Evidence for action. 2003. Available at: Http://www.who.int/chp/knowledge/publications/ adherence-full-report.pdf. Accessed March 15, 2011
16. New England Health Care Institute. Thinking outside the pillbox: A system-wide approach to improving patient medication adherence for chronic disease. 2009. Available at: Http://www. nehi.net/publications/44/thinking- outside-the-pillbox-a-systemwide-approach-to-improving-patient-medication- adherence-for-chronic-disease. Accessed March 15, 2011
17. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health. 2008;11: 44-47 (Pubitemid 351160875)
18. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30: 89-100
19. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256: 568-576
20. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2010;18: 69-77
21. Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: Direct and indirect costs. Curr Med Res Opin. 2009;25: 869-877
22. Phillips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis. Poster presented at American Academy of Neurology 62nd Annual Meeting, April 10-17, 2010; Toronto, Ontario, Canada
23. Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: Initial validation and association with self-report. Mult Scler. 2010;16: 112-120
24. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: A retrospective administrative claims analysis. Patient Prefer Adherence. 2011;5: 73-84
25. Tremlett HL, Oger J. Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61: 551-554 (Pubitemid 37025380)
26. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11: 306-309 (Pubitemid 40775187)
27. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin. 2010;26: 663-674
28. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7: 903-914
29. O'Connor P, Filippi M, Arnason B et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 2009;8: 889-897
30. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol. 2008;28: 56-68 (Pubitemid 351273084)
31. Caon C. Maximising therapeutic outcomes in patients failing on current therapy. J Neurol Sci. 2009;277(suppl. 1): S33-S36
32. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45: 1268-1276
33. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011;6: E16664
34. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: Impact on the course of relapsing-remitting multiple sclerosis. Mult Scler. 2009;15: 50-58
35. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43: 1130-1139 (Pubitemid 41587600)
36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40: 373-383 (Pubitemid 17055592)
37. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45: 613-619
38. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8: 469-476
39. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13: 618-625
40. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15: 565-574 (Pubitemid 44336271)
41. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11: 449-457 (Pubitemid 41022729)
42. Tan H, Yu J, Tabby D, Devries A, Singer J. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: A cohort study. Mult Scler 2010;16: 956-963
43. Patti F. Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence. Patient Prefer Adherence. 2010;4: 1-9
44. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59: 131-135 (Pubitemid 351301255)
45. Prosperini L, Borriello G, Fubelli F, Marinelli F, Pozzilli C. Natalizumab treatment in multiple sclerosis: The experience of S. Andrea MS Centre in Rome. Neurol Sci. 2011;31(suppl. 3): 303-307
46. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011;17: 708-719
47. Fernandez O, Alvarenga MP, Guerrero M, et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: Results of an observational study. Mult Scler. 2011;17: 192-197
48. Mancardi GL, Tedeschi G, Amato MP et al. Three years of experience: The Italian registry and safety data update. Neurol Sci. 2011;31(suppl. 3): 295-297
49. Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18: 240-245.